Tan Tock Seng Hospital
Singapore, 308433
Location status: Recruiting
NCT Number: NCT06073106
The aging population and its accompanying burden from non-communicable chronic diseases predicts an increasing impact imposed by frailty on healthcare systems. This is due to a lack of normative data for older adults and reliable risk stratification methods to develop effective approaches to the prevention of frailty.
In this study, the investigators plan to form a common dataset for phenotype identification, risk stratification of frailty and its targeted treatment plans in the at-risk and mildly frail population.
Interested in participating?
Request Info50 year and older
All sexes
Observational
Singapore, 308433
Location status: Recruiting
Osteosarcopaenia and multimorbidity have emerged as two key antecedent factors driving the cycle of frailty, leading to adverse outcomes. However, it remains unclear how multimorbidity and/or osteosarcopaenia act singly or in concert to influence the expression and trajectory of the frailty continuum.
OPTIMA-C will develop unifying administrative and data platforms, exploring the feasibility of inclusive screening for sarcopaenia early during rehabilitation hospital stay. Early muscle ultrasound will also be utilised to determine key muscles possibly predictive of rehabilitation functional or global outcomes in the studied populations and their correlation with acute disease outcomes. Digital markers are quantified and correlations are investigated with physical, muscle and bone imaging findings.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
For Knee Osteoarthritis patients only:
Time frame: Through study's data collection period, up to 4 years
Based off different outcomes determined in the study
Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)
Based on CFS - 9-point clinical assessment tool evaluating an individual's frailty status; maximum score: 9; higher score indicates increased frailty.
Time frame: For inpatient: Visit 3 (6 months post-event) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)
Measured using weak electrical current passed from feet to estimate proportion of muscle, fat and water mass.
Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)
Measures 3 components: (1) 5 times chair stand test; (2) Balance test; (3) Gait speed (4m walk test). Score from 0-12 with higher score indicating greater functional capacity.
Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)
Measured seated with arms on a table bent to 90° using a dynamometer (mean of 3 readings will be recorded)
Time frame: For Inpatient: Visit 1 (within 2 weeks of admission), Visit 2 (1 week pre-discharge)
Determines state of muscle health of arm, thigh and jaw muscles through size, area and structural properties.
Time frame: For inpatient: Visit 1 (within 2 weeks of admission) to Visit 6 (end of 3rd year); For outpatient: Visit 1 (baseline) to Visit 4 (end of 3rd year)
5-point questionnaire; (1-2 point) indicates pre-frail, (3-5 points) indicates frail
Contact information is provided by the study sponsor or research team.
Tan Tock Seng Hospital
Other
Targeting Osteosarcopaenia and Multimorbidity for Frailty Prevention Through Identification and Deep Phenotyping Methods in Healthy Aging and High-burden Disease Cohorts.
Acronym: OPTIMA-C
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05277519
Brain Diseases, Brain Injuries
Paris, France
View Trial DetailsNCT02795052
ALS, Alzheimer Disease
Westport, Connecticut, United States
View Trial DetailsNCT07635329
Blindness, Blindness, Cortical
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05183152
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Austin, Texas, United States
View Trial Details